Literature DB >> 29198371

Comparison of Abbott Architect®, Siemens Immulite®, and Diasorin Liaison® for determination of Epstein-Barr virus serological diagnosis.

Catherine François1, Christine Segard2, Maryline Bouvier2, Martine Stefanski2, Christine Pannier2, Patricia Zawadzki2, Catherine Roussel2, Denise Hecquet2, Gilles Duverlie3, Etienne Brochot3, Sandrine Castelain3.   

Abstract

This study compared the performance of 3 automated immunoassays, Architect® (Abbott), Immulite® (Siemens) and Liaison® (Diasorin), for Epstein-Barr virus (EBV) serology. Ninety-one serum samples collected in Amiens University Hospital were analyzed for the presence of Viral Capsid Antigen (VCA) IgG and IgM and Epstein-Barr Nuclear Antigen (EBNA) IgG. The agreement between the 3 assays was calculated for each marker individually and for determination of the EBV profile, based on interpretation of the combination of these 3 EBV markers. Although similar results were obtained with Architect® and Liaison®, several discordant results were observed with Immulite®, particularly for EBNA IgG. A large number of EBNA IgG-positive results were observed, which interfered with interpretation of the EBV profile. In contrast, Immulite® performed similarly to the 2 other assays for detection of VCA IgM.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Architect; EBV; Epstein–Barr virus; Immulite; Infectious mononucleosis; Liaison

Mesh:

Substances:

Year:  2017        PMID: 29198371     DOI: 10.1016/j.diagmicrobio.2017.10.020

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  Preliminary evaluation of a candidate international reference for Epstein-Barr virus capsid antigen immunoglobulin A in China.

Authors:  Hao Chen; Qiaohua Zhong; Xiaobin Wu; Yanling Ding; Qi Chen; Ning Xue; Yiwei Xu; Shulin Chen
Journal:  Infect Agent Cancer       Date:  2020-04-29       Impact factor: 2.965

2.  COVID-19 associated EBV reactivation and effects of ganciclovir treatment.

Authors:  Mei Meng; Sheng Zhang; Xuan Dong; Wenqing Sun; Yunfeng Deng; Wenzhe Li; Ranran Li; Djillali Annane; Zhixiong Wu; Dechang Chen
Journal:  Immun Inflamm Dis       Date:  2022-04

3.  Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis.

Authors:  Sargis Abrahamyan; Bettina Eberspächer; Muna-Miriam Hoshi; Lilian Aly; Felix Luessi; Sergiu Groppa; Luisa Klotz; Sven G Meuth; Christoph Schroeder; Thomas Grüter; Björn Tackenberg; Friedemann Paul; Florian Then-Bergh; Tania Kümpfel; Frank Weber; Martin Stangel; Antonios Bayas; Brigitte Wildemann; Christoph Heesen; Uwe Zettl; Clemens Warnke; Gisela Antony; Nicole Hessler; Heinz Wiendl; Stefan Bittner; Bernhard Hemmer; Ralf Gold; Anke Salmen; Klemens Ruprecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-05-05       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.